ArticleInternational journal of general medicine2026
Development and External Validation of a Clinically Applicable Model for Identifying Diabetic Kidney Disease in Population-Based and Clinical Cohorts.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease worldwide. Early identification of DKD remains challenging in routine clinical practice. Objective: We aimed to develop and externally validate a clinically accessible model integrating metabolic and renal biomarkers for identifying DKD among individuals with diabetes. Methods: Data from 3494 diabetic participants in the China Health and Retirement Longitudinal Study (CHARLS) were utilized for model development. Independent predictors were identified via multivariable logistic regression. To ensure robust generalizability, external validation was conducted in two independent cohorts: a national survey cohort from the National Health and Nutrition Examination Survey (NHANES) and a real-world clinical cohort from our hospital. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves and decision curve analysis (DCA). Results: The final model incorporated age, gender, the triglyceride-glucose (TyG) index, blood urea nitrogen and Cystatin C. In the CHARLS cohort, the model demonstrated robust discriminative power (AUC = 0.868) and excellent calibration. At the optimal cutoff (8.02%), the negative predictive value (NPV) reached 98.43%. In the NHANES validation, the model maintained high discriminative ability (AUC = 0.82). Crucially, in the hospital-based clinical cohort, the model demonstrated stable performance (AUC = 0.781, 95% CI: 0.648-0.888). DCA confirmed a consistent and significant net clinical benefit across a wide threshold range (0.2 to 0.8) in real world. Conclusion: The proposed model may serve as an adjunctive tool for identifying individuals with diabetes who have a high probability of prevalent DKD and who may therefore benefit from confirmatory kidney assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.